Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
GIST
Do you always send for SDHB by IHC for workup of GIST? or is NGS/FISH that includes SDHB sufficient?
Related Questions
Is there role of HER2 directed therapy in adjuvant treatment of colon adenocarcinoma for tumors that are HER2 3+ by IHC?
In the setting of total neoadjuvant therapy (TNT) for locally advanced rectal cancer, would you consider using FOLFIRI instead of FOLFOX/CAPOX for consolidative chemotherapy in patients unable to receive oxaliplatin, with the goal of maximizing the chance of clinical complete response and facilitating non-operative management?
What would your approach be for a locally advanced head and neck cancer diagnosed concurrently with a mid-esophageal cancer?
Are there any data (retrospective or otherwise) on the watch and wait approach in patients who achieve cCR after CRT without consolidation chemotherapy?
For a patient with metastatic colon cancer which is MSI-H/dMMR and BRAF V600E+, what would be your preferred first line treatment?
What are your top takeaways in GI Cancers from ESMO 2025?
Are you planning to start running IHC HER2 testing on all tumor types, even those where HER2 overexpression is less typical, in light of tumor agnostic approval of trastuzumab deruxtecan?
Are you using Tarlatamab for neuroendocrine carcinomas (NECs) and poorly differentiated neuroencocrine tumors of GI (non-lung) origins?
How do you reconcile the differing outcomes of the MATTERHORN and KEYNOTE-585 trials when determining systemic treatment approach for gastric/GEJ adenocarcinoma?
How would you approach first-line treatment for a patient with metastatic colon cancer who develops an anaphylactic reaction to cetuximab with FOLFOX/cetuximab/encorafenib?
